In August 2026, doctors in Berlin published something the rheumatoid arthritis field had been waiting years to see. Six people with severe RA that had resisted every available medicine received a single infusion of their own reprogrammed immune cells. All six improved. A year later, three of them needed no RA medication at all. It was the first trial of its kind, and it is tiny. But it points at a question that has never been on the table before: can RA be switched off rather than managed?
About 1.3 million US adults live with RA. This article covers what treatment looks like today, why a large group of patients still fall through the gaps, what researchers are testing right now, and where clinical trials fit in.
Looking for treatment options for rheumatoid arthritis?
Browse open RA clinical trials near you! We'll handle the follow-up.
What rheumatoid arthritis treatment includes today
The goal of RA care today is remission. That means no swollen joints, normal blood test results, and no pain holding you back from your day. Doctors get there with a plan called treat to target. You start on a medicine, check how active the disease is every few months, and adjust until you hit the goal.
Methotrexate is still where most people start. It has been the go to first medicine for decades because it works for a lot of people, is cheap, and doctors know it well. But it is not enough on its own for most people. In a Swedish study of 11,000 people with new RA, about half had not reached remission after three months on methotrexate alone. That is usually when the next step comes in.
Biologics. These are medicines given by injection or IV that block one specific signal driving inflammation. TNF blockers like adalimumab (Humira) have been the main option for almost 30 years. Others work differently: some block IL-6, some remove B cells (rituximab), some stop T cells from switching on (abatacept). There are more than ten to choose from, and if one stops working, switching to a different type often helps.
Targeted pills. JAK inhibitors are pills that block inflammation signals inside cells instead of outside them. They work about as well as biologics for many people and skip the injections, though they come with safety warnings that affect who can take them.
What changed in the guidelines. The 2025 European recommendations, published in early 2026, streamlined the guidance and clarified what to do when someone reaches stable remission: continuing treatment is preferred, though lowering the dose may be considered, since stopping altogether usually leads to a flare.
The gap nobody has closed yet
Here is the honest problem. Despite all those options, roughly 15 to 25 percent of people with severe RA still do not achieve adequate control, even after trying several biologics. And the medicines that do work require staying on them, often for life, because they hold the immune system down rather than fixing it.
Remission rates in real life also vary far more than they should. A 2025 study across England and Wales found that about one third of people with new RA reached remission at three months, and that the rate had barely moved since 2018. The difference between the best and worst hospitals was threefold. Where you are treated, and how fast, still shapes your outcome.
Immune reset with CAR T cells. The Berlin trial used CD19 CAR T cells, the same technology that changed blood cancer treatment, to clear out the B cells driving RA. Side effects were milder than what is typically seen in cancer patients, because people with RA have far fewer disease driving cells to begin with. A second phase, testing the cell therapy head to head against an approved B cell drug, is planned. The big question left is how long the reset lasts.
New mechanisms in the pipeline. Several drugs on our platform go after RA in ways no approved medicine does yet. Roche is testing RO7790121 in moderate to severe RA, Bristol Myers Squibb is studying BMS-986528 in people whose RA has not responded to other treatments, and a dose finding study of the oral drug AP1189 is testing a new anti inflammatory pathway. Two of these studies recruit exactly the group with the fewest options: people whose RA has resisted treatment. The AP1189 study takes the opposite approach and enrolls people newly diagnosed, before they have started any RA medicine.
Not everything is a drug. An at home ultrasound therapy study is testing a device instead of a medicine. A probiotics trial is asking whether gut bacteria affect how active the disease is. And a study on exercise dosing is figuring out how much movement actually helps people with arthritis, including RA, something with real evidence behind it that does not need a prescription.
Lungs and the whole body. About 1 in 10 people with RA develop lung scarring called interstitial lung disease, so a study following RA patients at risk for lung disease is watching to catch it early. A large 2023 analysis also found that people taking the JAK inhibitor tofacitinib had fewer new lung problems than people on adalimumab, a difference researchers say is worth testing directly in its own trial.
Why RA research takes time
The measurement problem. Doctors score how active RA is by counting sore and swollen joints, checking blood markers, and asking how you feel. It works, but part of it depends on judgment, and RA trials often see a real placebo effect. So proving a new drug beats a placebo on top of methotrexate takes hundreds of people and months of watching how they do.
The crowded field problem. With more than a dozen good drugs already approved, a new one has to be better, safer, or work for people the others do not help. That last group is small and scattered across many clinics, which makes it slow to find enough people for a trial.
The immune system problem. Every approved RA drug holds back the immune system, which means more infection risk and treatment for life. Reset therapies like CAR T aim to offer something different, but they are hard to make, and each trial so far has only treated a handful of people. Scaling that up safely is the challenge of the next five years.
The representation problem. RA affects women about three times as often as men, and it is often more severe in Black and Hispanic patients, yet those groups are still underrepresented in trials. A study in England and Wales found that Black patients had lower odds of reaching remission, even after accounting for other factors. Several current studies name diverse enrollment as a goal. Here's why diversity in clinical trials matters so much.
Common myths about rheumatoid arthritis
"RA is just arthritis from getting older."
No. That is osteoarthritis, which comes from cartilage wearing down over time. RA is different, it is an autoimmune disease that can start at 25 just as easily as 65, and it needs its own kind of treatment.
"You just have to live with the pain."
Not true anymore. The goal of modern care is remission, and many people get there. If your current treatment still leaves you with active disease, that is a reason to talk to your doctor about changing the plan, not a reason to accept it.
"RA only affects the joints."
RA raises your risk of heart disease, affects the lungs in some form in about 1 in 5 people, including scarring in about 1 in 10, and can cause deep tiredness. That is why good RA care looks at your whole body, not just your hands.
"Diet can cure RA."
No diet cures RA. Some ways of eating may ease symptoms, and researchers are studying probiotics, but nothing takes the place of disease modifying medicine.
How RA is measured, and what care usually looks like
RA does not have a stage 1 to 4 system like some diseases. Instead, doctors track how active it is with scores like DAS28 or CDAI, and sort it into remission, low, moderate, or high. If activity is moderate or high, medicines get added or changed until the score comes down. In remission, the focus shifts to keeping it that way, and sometimes carefully lowering the dose. This describes usual practice, not a recommendation, your plan belongs to you and your rheumatologist.
For trials, these scores are what decide eligibility. Most treatment studies want people with moderate to high activity despite their current treatment, and they often ask for antibody status too, anti CCP or rheumatoid factor. Knowing your last score and your antibody results lets you filter studies in minutes.
How to find a rheumatoid arthritis clinical trial
AllClinicalTrials.com lists RA studies recruiting across the US, from new oral drugs to exercise programs and lung screening. Right now that includes a Roche study testing a new drug for RA that has not responded to TNF blockers or JAK inhibitors, and a study following RA patients at risk for lung disease to catch it early.
The application takes about 5 minutes: you answer questions about your diagnosis, current medicines, and disease activity, and if a study near you looks like a match, the research team contacts you. Nothing is decided until you have gone through informed consent, and participation is voluntary at every step.
Three things to have ready: your most recent disease activity score if you know it, your antibody status, and the list of RA medicines you have tried. Those three answers decide eligibility for most RA studies.
Common questions
What is the first line treatment for rheumatoid arthritis? Methotrexate, usually started soon after diagnosis. If disease activity stays high after a few months, a biologic or a JAK inhibitor is typically added.
What is the newest treatment for rheumatoid arthritis? The most talked about development is CD19 CAR T cell therapy. In the first published trial in 2026, all six treatment resistant patients improved and three reached medication free remission. It is experimental and available only in trials.
Can rheumatoid arthritis go into remission? Yes. Remission means little or no active disease on standard scores, and it is the goal of modern treatment. Many people reach it on medication, and tapering is now a supported option for people who stay in stable remission.
Do RA trials use placebo? Usually not instead of treatment. In most RA drug trials, everyone stays on background therapy such as methotrexate, and the study drug or a placebo is added on top. Leaving active RA untreated would be unethical, and trial designs reflect that.
See rheumatoid arthritis clinical trials recruiting now
Browse open studies, filter by location, and apply in about 5 minutes: Rheumatoid Arthritis Clinical Trials